Pharmacyclics Inc $116.91

down -3.53


1/8/2014 04:00 PM  |  NASDAQ : PCYC  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get PCYC Trend Analysis - it has underperformed the S&P 500 by 10%

Partner Headlines

  1. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD
  2. Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

    Benzinga
  3. Pharmacyclics

    IBD
  4. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga
  5. AbbVie Beats Q1 Estimates, Downplays HCV 'Price War'

    IBD
  6. Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite ...

    Benzinga
  7. Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva ...

    Benzinga
  8. Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with ...

    Benzinga
  9. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  10. Morgan Stanley Starts Pharmacyclics With Equal-Weight; $120 PT -Reuters

    Benzinga
  11. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, ...

    Benzinga
  12. Pharmacyclics target raised

    IBD
  13. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD
  14. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga
  15. WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses

    IBD
  16. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus
  17. Pharmacyclics Hits High As Imbruvica Launches Big

    IBD
  18. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga
  19. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  20. Pharmacyclics up on FDA OK

    IBD
  21. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  22. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  23. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  24. ETF Outlook for Wednesday, January 8, 2014 (ROBO, PBE, SMH, EUFN)

    Benzinga
  25. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  26. Biotechs Jump On Drug News

    IBD
  27. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  28. The Top Five Drug Launches Of 2013

    IBD
  29. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

    Benzinga
  30. Qihoo, Noah Lead IBD 50's Top 5 Young Chinese Stocks

    IBD
  31. Pharmacyclics Announces Ibrutinib Frontline Chronic Lymphocytic Leukemia ...

    Benzinga
  32. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD
  33. 2 Top Biotechs Presenting Data At Hematology Event

    IBD
  34. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD
  35. SouFun, Zeltiq Lead IBD's Top 5 With Bolting RS Lines

    IBD
  36. UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech ...

    Benzinga
  37. Wedbush Reiterates on Pharmacyclics as IMBRUVICA Approved for Mantle Cell ...

    Benzinga
  38. Market Wrap For November 13: Markets Await Janet Yellen's Big Day Thursday

    Benzinga
  39. Pharmacyclics Drug Wins One Approval, Awaits Another

    IBD
  40. The U.S. Food and Drug Adminstration Approves Pharmacyclis Product For ...

    Benzinga
  41. Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

    Benzinga
  42. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga
  43. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, ...

    Benzinga
  44. Pharmacyclics' Ibrutinib Could Crown Turnaround Story

    IBD
  45. J&J Reporting Q3 Earnings As Sentiment Edges Up

    IBD
  46. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  47. Gilead Stock Jumps On Leukemia Drug News

    IBD
  48. Pharmacyclics hits new high

    IBD
  49. Pharmacyclics Hits New High As Bulls Launch Coverage

    IBD
  50. UPDATE: J.P. Morgan Initiates Coverage on Pharmacyclics on Ibrutinib Potential

    Benzinga
Trading Center